Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Clears Broad Range of Indications for Depression Treatment Device - Medical Product Outsourcing

FDA Clears Broad Range of Indications for Depression Treatment Device

Brainsway product targets patients unresponsive to therapy.

Brainsway Ltd., a Jerusalem, Israel-based provider of transcranial magnetic stimulation (TMS) systems for the treatment of neurological and psychopathological disorders, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a system that treats depression. The Deep TMS device is designed for depressed patients who do not respond to therapy.

TMS involves non-invasive but specific stimulation of brain tissue using brief magnetic pulses.

Company officials note that FDA’s cleared indications for the Deep TMS device are particularly broad, which could be indicative of the device’s efficacy in treating depression and a milestone for changing treatments for the disorder. U.S. regulatory approval opens up a potential billion-dollar market to Brainsway.

According to a company statement, Brainsway executives are considering how to market and distribute the Deep TMS device in the United States and other countries, including collaborations with companies that have experience in the business.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters